Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary) ; Cisplatin
- Indications Cervical cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 10 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
- 10 Aug 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2022.
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.